U.S. markets open in 2 hours 7 minutes

Invitae Corporation (NVTA)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
39.04-2.97 (-7.07%)
At close: 4:00PM EST

38.14 -0.90 (-2.31%)
Pre-Market: 7:20AM EST

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close42.01
Bid0.00 x 1100
Ask37.68 x 900
Day's Range37.71 - 41.85
52 Week Range7.41 - 61.59
Avg. Volume4,521,050
Market Cap7.677B
Beta (5Y Monthly)2.03
PE Ratio (TTM)N/A
EPS (TTM)-4.47
Earnings DateFeb 17, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est54.60
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Should You Buy Invitae Stock?
    Motley Fool

    Should You Buy Invitae Stock?

    The past 12 months have been a wild ride for the genetic testing company's stock, with a sub-$10 low and a high of more than $60.

  • Why Invitae Stock Fell Today
    Motley Fool

    Why Invitae Stock Fell Today

    What happened Shares of Invitae (NYSE: NVTA) had fallen 6.6% as of 3:13 p.m. EST on Wednesday. The medical genetics company didn't announce any news that would cause the stock to drop. Instead, Invitae's decline today appears to be part of a broader sell-off of high-growth stocks, with the Nasdaq Composite Index falling 2%.

  • PR Newswire

    Pharming Group, in collaboration with Invitae Corporation, launches genetic testing program 'navigateAPDS' in US and Canada

    Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global, commercial stage biopharmaceutical company developing innovative protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs, in collaboration with Invitae Corporation (NYSE: NVTA, "Invitae"), a leading medical genetics company, announces the launch of a sponsored genetic testing program, navigateAPDS, designed to assist clinicians in identifying patients and their family members with activated PI3K delta syndrome (APDS), which may lead to earlier diagnosis.